11/15/2013

A marketing authorization application was filed by Boehringer Ingelheim in Europe for Spiriva Respimat, or tiotropium, as a treatment for asthma patients 18 and older. The application is based on late-stage trial results involving more than 4,000 patients in over 150 locations worldwide.

Related Summaries